Please use a minimum of three unique search wordsOur search is configured to only display links relevant to answer your question. For the best results please use specific and relevant keywords that accurately reflect the information you are seeking.Please do not use this field to report adverse events or product complaints. Adverse events and product complaints should be reported. Reporting forms and information can be found at UK: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events and product complaints should also be reported to Lilly: please call Lilly UK on 01256 315 000.
Taltz ® (ixekizumab)
This information is intended for UK registered healthcare professionals only as a scientific exchange in response to your search for information. Please refer to the link for full prescribing information:
Taltz Summary of Product Characteristics (SmPC)
Taltz® (ixekizumab): Premedication Use Prior to Injection
The decision whether to premedicate a patient should be made at the discretion of the prescribing physician.
Protocols for Premedication in the Clinical Trials
According to the protocols for psoriasis and psoriatic arthritis, and axSpA (including AS/r-axSpA and nr-axSpA) trials, if a patient experienced an acute allergic/hypersensitivity reaction after injection of investigational product, consideration for any premedication for future injections was agreed upon between the investigator and sponsor and/or its designee.
Medications considered appropriate for premedication included but were not restricted to acetaminophen/paracetamol up to 1000 mg and antihistamines (for example, oral diphenhydramine 50 mg), given 30 to 60 minutes prior to investigational product injection.
Patients were permitted to self-premedicate at home prior to administration of investigational product as directed by the investigator.1,2
Examples of potential allergic/hypersensitivity reactions that might merit premedication included
mild-to-moderate skin rashes
mild-to-moderate generalized pruritus or urticaria, and
mild-to-moderate ISRs (eg, injection-site erythema, injection-site pruritus, etc).1,2
Please note that ixekizumab is contraindicated in patients with serious hypersensitivity to the active substance or to any of the excipients.3
Premedication in Clinical Trials
Of patients experiencing an ISR during the induction period of UNCOVER-1, -2, and -3, one patient who received ixekizumab used premedication for ISR when taking future injections.2
No patients who received ixekizumab during the 24-week double-blind treatment periods of SPIRIT-P1 and SPIRIT-P2 used premedication for ISR with future injections.2
No analysis has been conducted on patients who used premedication for ISR with future injections in axSpA trials.
1. Gordon KB, Blauvelt A, Papp KA, et al. Phase 3 trials of ixekizumab in moderate-to-severe plaque psoriasis. N Engl J Med. 2016;375(4):345-356. http://dx.doi.org/10.1056/NEJMoa1512711
2. Data on file, Eli Lilly and Company and/or one of its subsidiaries.
3. Taltz [summary of product characteristics]. Eli Lilly Nederland B.V., The Netherlands.
Glossary
AS/r-axSpA = ankylosing spondylitis/radiographic axial spondyloarthritis
axSpA = axial spondyloarthritis
ISR = injection site reaction
nr-axSpA = nonradiographic axial spondyloarthritis
Date of Last Review: September 25, 2020
Contact Lilly
Call or Email us
If you want to ask a Medical Information question or you want to report an adverse event or product complaint you can call us or email us at ukmedinfo@lilly.com
Available Mon - Fri, 10am - 4pm, excluding Bank Holidays